140 related articles for article (PubMed ID: 30441967)
21. Gastric dysplasias. A clinicopathological study of 35 cases.
Chlumská A; Mukenšnabl P; Waloschek T; Zámečník M
Cesk Patol; 2013 Jan; 49(1):35-8. PubMed ID: 23432074
[TBL] [Abstract][Full Text] [Related]
22. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia.
Lu D; Vohra P; Chu PG; Woda B; Rock KL; Jiang Z
Am J Surg Pathol; 2009 Apr; 33(4):521-5. PubMed ID: 19047899
[TBL] [Abstract][Full Text] [Related]
23. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
[TBL] [Abstract][Full Text] [Related]
24. Pyloric gland adenoma: a histologic, immunohistochemical and molecular genetic study of 23 cases.
Chlumská A; Waloschek T; Mukenšnabl P; Martínek P; Kašpírková J; Zámečník M
Cesk Patol; 2015; 51(3):137-43. PubMed ID: 26421956
[TBL] [Abstract][Full Text] [Related]
25. Differentiation reprogramming in gastric intestinal metaplasia and dysplasia: role of SOX2 and CDX2.
Camilo V; Garrido M; Valente P; Ricardo S; Amaral AL; Barros R; Chaves P; Carneiro F; David L; Almeida R
Histopathology; 2015 Feb; 66(3):343-50. PubMed ID: 25196071
[TBL] [Abstract][Full Text] [Related]
26. CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cancer.
Liu Q; Teh M; Ito K; Shah N; Ito Y; Yeoh KG
Mod Pathol; 2007 Dec; 20(12):1286-97. PubMed ID: 17906616
[TBL] [Abstract][Full Text] [Related]
27. CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance.
Park DY; Srivastava A; Kim GH; Mino-Kenudson M; Deshpande V; Zukerberg LR; Song GA; Lauwers GY
Mod Pathol; 2010 Jan; 23(1):54-61. PubMed ID: 19820687
[TBL] [Abstract][Full Text] [Related]
28. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma.
Takubo K; Aida J; Naomoto Y; Sawabe M; Arai T; Shiraishi H; Matsuura M; Ell C; May A; Pech O; Stolte M; Vieth M
Hum Pathol; 2009 Jan; 40(1):65-74. PubMed ID: 18755496
[TBL] [Abstract][Full Text] [Related]
29. Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia.
Takubo K; Vieth M; Aida J; Sawabe M; Kumagai Y; Hoshihara Y; Arai T
Digestion; 2009; 80(4):248-57. PubMed ID: 19828957
[TBL] [Abstract][Full Text] [Related]
30. Dynamics of SOX2 and CDX2 Expression in Barrett's Mucosa.
Barros R; Pereira D; Callé C; Camilo V; Cunha AI; David L; Almeida R; Dias-Pereira A; Chaves P
Dis Markers; 2016; 2016():1532791. PubMed ID: 27766003
[TBL] [Abstract][Full Text] [Related]
31. [Barrett's esophagus: diagnosis and therapy].
Schmassmann A; Gebbers JO
Praxis (Bern 1994); 2005 May; 94(21):861-8. PubMed ID: 15966485
[TBL] [Abstract][Full Text] [Related]
32. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.
Huhta H; Helminen O; Lehenkari PP; Saarnio J; Karttunen TJ; Kauppila JH
Oncotarget; 2016 Apr; 7(17):23658-67. PubMed ID: 27008696
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence.
Hayes S; Ahmed S; Clark P
J Clin Pathol; 2011 Feb; 64(2):110-3. PubMed ID: 21106545
[TBL] [Abstract][Full Text] [Related]
35. Histopathology of columnar-lined esophagus in patients with gastroesophageal reflux disease.
Lenglinger J; Ringhofer C; Eisler M; Sedivy R; Wrba F; Zacherl J; Cosentini EP; Prager G; Haefner M; Riegler M
Wien Klin Wochenschr; 2007; 119(13-14):405-11. PubMed ID: 17671821
[TBL] [Abstract][Full Text] [Related]
36. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus.
Shi XY; Bhagwandeen B; Leong AS
Am J Clin Pathol; 2008 Apr; 129(4):571-7. PubMed ID: 18343784
[TBL] [Abstract][Full Text] [Related]
37. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
38. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression.
Reis CA; David L; Correa P; Carneiro F; de Bolós C; Garcia E; Mandel U; Clausen H; Sobrinho-Simões M
Cancer Res; 1999 Mar; 59(5):1003-7. PubMed ID: 10070955
[TBL] [Abstract][Full Text] [Related]
39. Risks and Predictors of Gastric Adenocarcinoma in Patients with Gastric Intestinal Metaplasia and Dysplasia: A Population-Based Study.
Li D; Bautista MC; Jiang SF; Daryani P; Brackett M; Armstrong MA; Hung YY; Postlethwaite D; Ladabaum U
Am J Gastroenterol; 2016 Aug; 111(8):1104-13. PubMed ID: 27185078
[TBL] [Abstract][Full Text] [Related]
40. Distinguishing Barrett gastric foveolar dysplasia from reactive cardiac mucosa in gastroesophageal reflux disease.
Patil DT; Bennett AE; Mahajan D; Bronner MP
Hum Pathol; 2013 Jun; 44(6):1146-53. PubMed ID: 23332925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
